Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Giaccone

Showing results (211-220 of 359) with videos related to

Pageof 36
Sort By:
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
In vitro sequence-dependent synergistic effect of suramin and camptothecinR Lopez, G J Peters, E Smitskamp-Wilms, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1997
Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative GroupA Ardizzoni, H Hansen, P Dombernowsky, et al.
European Journal of Cancer (Oxford, England : 1990)|June 9, 2006
Docetaxel and cisplatin as induction chemotherapy in patients with pathologically-proven stage IIIA N2 non-small cell lung cancer: a phase II study of the European organization for research and treatment of cancer (EORTC 08984)B Biesma, C Manegold, H J M Smit, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 15, 1993
Synthetic peptides homologous to prion protein residues 106-147 form amyloid-like fibrils in vitroF Tagliavini, F Prelli, L Verga, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 1, 1992
Prion protein preamyloid and amyloid deposits in Gerstmann-Sträussler-Scheinker disease, Indiana kindredG Giaccone, L Verga, O Bugiani, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1996
Dose-intensive chemotherapy with doxorubicin, cyclophosphamide and GM-CSF fails to improve survival of metastatic breast cancer patientsA H Honkoop, K Hoekman, J Wagstaff, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 12, 2018
Design and conduct of early clinical studies of immunotherapy agent combinations: recommendations from the task force on Methodology for the Development of Innovative Cancer TherapiesM Smoragiewicz, J Bogaerts, E Calvo, et al.
Oncogene|March 21, 2006
Subcellular localization and nucleocytoplasmic transport of the chromosomal passenger proteins before nuclear envelope breakdownJ A Rodriguez, S M A Lens, S W Span, et al.
Lung Cancer (Amsterdam, Netherlands)|April 28, 2001
Topoisomerase IIalpha and other drug resistance markers in advanced non-small cell lung cancerA C Dingemans, J van Ark-Otte, S Span, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1991
Phase II study of ACNU in non-small-cell lung cancer: EORTC study 08872A S Planting, A Ardizzoni, J Estapé, et al.
Pageof 36

Showing results (211-220 of 359) with videos related to

Sort By:
Pageof 36
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
In vitro sequence-dependent synergistic effect of suramin and camptothecinR Lopez, G J Peters, E Smitskamp-Wilms, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1997
Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative GroupA Ardizzoni, H Hansen, P Dombernowsky, et al.
European Journal of Cancer (Oxford, England : 1990)|June 9, 2006
Docetaxel and cisplatin as induction chemotherapy in patients with pathologically-proven stage IIIA N2 non-small cell lung cancer: a phase II study of the European organization for research and treatment of cancer (EORTC 08984)B Biesma, C Manegold, H J M Smit, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 15, 1993
Synthetic peptides homologous to prion protein residues 106-147 form amyloid-like fibrils in vitroF Tagliavini, F Prelli, L Verga, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 1, 1992
Prion protein preamyloid and amyloid deposits in Gerstmann-Sträussler-Scheinker disease, Indiana kindredG Giaccone, L Verga, O Bugiani, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1996
Dose-intensive chemotherapy with doxorubicin, cyclophosphamide and GM-CSF fails to improve survival of metastatic breast cancer patientsA H Honkoop, K Hoekman, J Wagstaff, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 12, 2018
Design and conduct of early clinical studies of immunotherapy agent combinations: recommendations from the task force on Methodology for the Development of Innovative Cancer TherapiesM Smoragiewicz, J Bogaerts, E Calvo, et al.
Oncogene|March 21, 2006
Subcellular localization and nucleocytoplasmic transport of the chromosomal passenger proteins before nuclear envelope breakdownJ A Rodriguez, S M A Lens, S W Span, et al.
Lung Cancer (Amsterdam, Netherlands)|April 28, 2001
Topoisomerase IIalpha and other drug resistance markers in advanced non-small cell lung cancerA C Dingemans, J van Ark-Otte, S Span, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1991
Phase II study of ACNU in non-small-cell lung cancer: EORTC study 08872A S Planting, A Ardizzoni, J Estapé, et al.
Pageof 36